We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Bracco

Offers products, injectors and solutions portfolio for all diagnostic applications from constrast media to medical de... read more Featured Products: More products

Download Mobile App




Bracco Imaging Acquires Blue Earth Diagnostics to Expand Portfolio

By MedImaging International staff writers
Posted on 06 Jul 2019
Image
Image
Bracco Imaging S.p.A. (Milan, Italy) has signed a definitive agreement to acquire Blue Earth Diagnostics (Oxford, UK), a molecular imaging company.

Bracco Imaging, which is in the diagnostic imaging business, develops, manufactures and markets diagnostic imaging agents and solutions. The company offers a product and solution portfolio for all key diagnostic imaging modalities and its diagnostic imaging portfolio is completed by a range of medical devices and advanced administration systems for contrast imaging products.

Blue Earth Diagnostics is focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. The company's first approved and commercially available product is Axumin (F18-fluciclovine), a novel molecular imaging agent approved in the US and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. The company's pipeline includes Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid ("rh") agents, a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. The company will be a subsidiary of Bracco Imaging and will retain the Blue Earth Diagnostics name.

"Blue Earth Diagnostics' innovative products and pipeline will significantly enhance Bracco Imaging's portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties," said Fulvio Renoldi Bracco, Chief Executive Officer, Bracco Imaging. "We are thrilled to welcome to Bracco this world class team with exceptional product development and commercialization expertise."

"The acquisition of Blue Earth Diagnostics by Bracco Imaging is a validation of the proven success of Axumin in prostate cancer, its potential uses beyond prostate cancer, and the PSMA pipeline under development," said Dr. Jonathan Allis, D.Phil., Chief Executive Officer, Blue Earth Diagnostics. "Bracco Imaging's global footprint and clinical research and marketing support will enable us to further leverage our high-value platform for innovative radiopharmaceuticals to inform clinical management and guide care for cancer patients around the world."

Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Ultrasound Imaging System
P12 Elite
Digital Radiographic System
OMNERA 300M
Pocket Fetal Doppler
CONTEC10C/CL

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.